



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 March 2023
EMA/CHMP/119919/2023
Human Medicines Division

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product

Briviact/ brivaracetam

<common name>

Pharmaceutical form(s): See Annex A of the CHMP Opinion

Strength(s): See Annex A

Route(s) of administration: See Annex A

Packaging and package size(s): See Annex A

Number(s) in the Community Register of Medicinal Products: See Annex A

Marketing Authorisation Holder (MAH):

Name and address of the MAH: UCB Pharma S.A.
Allee de la Recherche 60
B-1070 Brussels
BELGIUM

Procedure

Procedure number: EMEA/H/C/003898/IB/0038

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

-the development of this product has complied with all measures in the agreed paediatric investigation plan PIP EMEA-000332-PIP01-08-M16. All studies in the agreed paediatric investigation plan P/0174/2021 were conducted after the entry into force of that Regulation,

-the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

